業(yè)務(wù)咨詢
中國:
Email: marketing@medicilon.com.cn
業(yè)務(wù)咨詢專線:400-780-8018
(僅限服務(wù)咨詢,其他事宜請撥打川沙總部電話)
川沙總部電話: +86 (21) 5859-1500
海外:
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
藥物代謝與藥代動力學(xué)(DMPK)主要研究藥物的吸收、分布、代謝和排泄的動態(tài)過程與規(guī)律,評估藥物的 DMPK特征對藥物的前期開發(fā)和后期臨床精準(zhǔn)用藥至關(guān)重要。DMPK是橋接藥理學(xué)、毒理學(xué)、藥劑學(xué)、藥物化學(xué)、乃至轉(zhuǎn)化醫(yī)學(xué)和精準(zhǔn)醫(yī)學(xué)的重要橋梁。
第26屆國際藥物及化學(xué)異物代謝學(xué)會北美會議(ISSX)將于2024年9月15日至18日在美國夏威夷召開,會議內(nèi)容涵蓋藥物代謝、藥代動力學(xué)、臨床藥理學(xué)、生物分析和藥物毒理學(xué)等領(lǐng)域。國際藥物及化學(xué)異物代謝學(xué)會(International Society for the Study of Xenobiotics,ISSX)是藥物代謝研究的最高學(xué)術(shù)組織之一,主要致力于全球范圍內(nèi)從事藥物與化學(xué)異物代謝方面的學(xué)術(shù)交流和國際合作。美迪西受邀參加本次年會,美迪西創(chuàng)始人&CEO陳春麟博士與美迪西DMPK專家們期待與您相聚在104號展位。
時(shí)間 | 9.15-9.18
地點(diǎn) | Hilton Hawaiian Village Waikiki Beach Resort, Honolulu
美迪西展位 | 104,不見不散!
為了展示美迪西創(chuàng)新實(shí)力和技術(shù)服務(wù)平臺最新進(jìn)展,美迪西藥代動力學(xué)/毒代動力學(xué) (DMPK/TK) 負(fù)責(zé)人蔣品博士將以海報(bào) (Poster) 形式分享以下主題的精彩內(nèi)容:
Title: Enhancing Drug - Drug Interaction Prediction by Integrating Physiologically- Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4
Session Time: Wednesday, September 18, 2024 12:30?2:30 PM
Location: Poster Session 3
Poster Number: P270
Presenting Author: Dr. Pin Jiang, Senior Director of DMPK at Medicilon
Dr. Pin Jiang Senior Director of DMPK
Dr. Pin Jiang holds a Ph.D. from China Pharmaceutical University in collaboration with School of Pharmacy, Fudan University. Dr. Jiang is postdoctoral fellow in DMPK and Pharmacometrics at Fudan University, specializes in the development of DMPK/TK for innovative drugs. He has also published papers in international journals such as DMD, EODMT, JSS and JPBA.
Having worked in the pharmaceutical R&D field for nearly 10years. Before joining Medicilon, Dr. Jiang held positions in the DMPK/TK and clinical pharmacology departments of well-known Biotech/Pharma/CRO companies (AstraZeneca Dizal Pharma, Covance, ChemPartner), focusing on small and large molecules. Dr. Jiang has been responsible for or involved in supporting hundreds of DMPK projects, including drugs, which have been approved by the Chinese NMPA and the US FDA for clinical research or market entry.
Dr. Jiang also holds significant professional affiliations, serving as a youth committee member of the Drug Metabolism Committee of the Chinese Pharmacological Society (CSSX), a committee member of the Drug Metabolism Committee of the Shanghai Pharmacological Society, a youth committee member of the Pharmacology Committee of the Shanghai Pharmaceutical Association, and a member of the International Society for the Study of Xenobiotics (ISSX).
Dr. Peggy Teng, Executive Director BD Operations
Dr. Karsten Holm, Director of Business Development
Dr. Mingzhu Zhang, VP of Business Development
美迪西的臨床前藥代動力學(xué)服務(wù)部門擁有一批理論知識扎實(shí)、實(shí)驗(yàn)經(jīng)驗(yàn)豐富的高級專業(yè)人才,統(tǒng)領(lǐng)著實(shí)驗(yàn)設(shè)計(jì)、實(shí)驗(yàn)實(shí)施、生物分析和數(shù)據(jù)分析等的工作。
我們的藥代動力學(xué)實(shí)驗(yàn)室已經(jīng)通過NMPA的GLP認(rèn)證,實(shí)驗(yàn)研究遵循ICH、NMPA和FDA的指導(dǎo)原則,可以根據(jù)客戶需求設(shè)計(jì)并開展體內(nèi)、體外藥代動力學(xué)試驗(yàn),為客戶提供一整套藥代動力學(xué)評價(jià)和優(yōu)化服務(wù)。美迪西藥代動力學(xué)服務(wù)高質(zhì)量的數(shù)據(jù)、高效率的實(shí)驗(yàn)周期,滿足客戶從早期藥物發(fā)現(xiàn)到新藥申報(bào)的需求,受到國內(nèi)外眾多客戶的好評。